NCT06608498

Brief Summary

The goal of this clinical trial is to learn if a single-session digital intervention (SPARK Coping) is acceptable, usable, and demonstrates a preliminary signal of efficacy in reducing symptom-related distress and increasing positive treatment-seeking attitudes among college students reporting subthreshold symptoms associated with risk for psychosis. Research questions inclue:

  • Does SPARK Coping reduce symptom-related distress and increase positive treatment seeking attitudes (primary outcomes) relative to a waitlist control condition?
  • Does SPARK Coping increase adaptive coping and reduce internalized stigma (primary targets) relative to a waitlist control condition? Researchers will compare provision of SPARK Coping to a waitlist control condition and collect data from participants on each of the variables described above. Participants will:
  • Complete questionnaires and surveys remotely at the start of the study and two weeks later
  • Be offered access to the SPARK Coping intervention either after completion of their baseline assessment (intervention arm) or after two weeks (waitlist control arm).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 23, 2024

Completed
11 days until next milestone

Study Start

First participant enrolled

October 4, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 6, 2025

Completed
Last Updated

December 17, 2025

Status Verified

December 1, 2025

Enrollment Period

3 months

First QC Date

September 19, 2024

Last Update Submit

December 11, 2025

Conditions

Keywords

College student mental health

Outcome Measures

Primary Outcomes (4)

  • Change in coping self-efficacy

    Caregiver coping self-efficacy will be assessed with the Coping Self-Efficacy Scale, a 26-item self-report questionnaire measuring the perceived ability of coping with various life challenges. Responses are rated on a 0 to 10 scale, and scores range from 0 to 260, with higher scores denoting a greater sense of self-efficacy in coping.

    Baseline, 2 weeks

  • Change in internalized stigma

    Internalized stigma will be assessed with the Internalized Stigma of Mental Health Inventory, Brief (ISMI-9). The ISMI-9 is a nine-item self-report short form, where each item is rated on a four-point Likert scale (1 = Strongly disagree, 4 = Strongly agree), and higher scores indicate more severe internalization of mental illness stigma.

    Baseline, 2 weeks

  • Change in attitudes toward treatment

    Help-Seeking Attitudes will be measured using the treatment and treatment-seeking subscales of the Endorsed and Anticipated Stigma Inventory (EASI). The full EASI is a 40-item self-reported questionnaire with subscales measuring beliefs about mental illness, beliefs about mental health treatment, beliefs about mental health treatment seeking, concerns about stigma from loved ones, and concerns about stigma from the workplace. The subscales are scored by summing the ratings from the eight individual items in each subscale (5-point scale with 1 = Strongly disagree, 5 = Strongly agree), with lower scores indicating less stigma, and more positive attitudes towards treatment and treatment-seeking. We will assess attitudes toward treatment and treatment-seeking by administering those two subscales. Total scores combining these two scales range from 16 to 80.

    Baseline, 2 weeks

  • Change in positive psychosis symptom frequency and distress

    Distress related to positive psychosis symptoms will be assessed with the CAPE-P15, a 15-item measure of positive symptoms of psychosis and psychosis risk as well as distress associated with such experiences. These 15 items are rated both on frequency (1 = Never to 4 = Nearly always) and distress (1 = Not distressed to 4 = Very distressed).

    Baseline, 2 weeks

Secondary Outcomes (2)

  • Change in recovery

    Baseline, 2 weeks

  • Change in general psychopathology / distress

    Baseline, 2 weeks

Study Arms (2)

Intervention (SPARK Coping)

ACTIVE COMPARATOR

Participants will be given a link to SPARK Coping immediately following their baseline assessments are complete.

Behavioral: SPARK Coping

Waitlist Control

NO INTERVENTION

Participants will wait until their follow-up assessment to be given access to the SPARK Coping intervention.

Interventions

SPARK CopingBEHAVIORAL

SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.

Intervention (SPARK Coping)

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Symptoms indicating risk for psychosis (a distress score \>= 20 on the Prodromal Questionnaire, Brief \[PQ-B\], per Savill et al., 2018; Early Intervention in Psychiatry and a positive frequency average score \>= 1.47 on the Community Assessment of Psychic Experiences (CAPE-P15), per Jaya et al., 2021 and Bukenaite et al., 2017)
  • Residence in the United States
  • Currently enrolled in a post-secondary college program at the University of Washington.

You may not qualify if:

  • Inconsistent or implausible reporting of symptoms at screening as determined by empirically-determined methods for detecting malingering or inconsistency
  • Failure to demonstrate understanding of study details in comprehension screening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Washington

Seattle, Washington, 98195, United States

Location

MeSH Terms

Conditions

Prodromal SymptomsPsychotic Disorders

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsSchizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Ben Buck, PhD

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor; Department of Psychiatry and Behavioral Sciences

Study Record Dates

First Submitted

September 19, 2024

First Posted

September 23, 2024

Study Start

October 4, 2024

Primary Completion

January 6, 2025

Study Completion

January 6, 2025

Last Updated

December 17, 2025

Record last verified: 2025-12

Locations